Description General description A cell-permeable pyrrazolopyrimidine compound that inhibits against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity (IC50 = 25.1, 148, and 234.6 nM, respectively), while exhibiting much reduced or little effect toward ALK5/TGFβR-I, ZAPK, Syk, PKCθ, PKA, or JAK3. Shown to block both BMP pathway-dependent dorsoventral development (EC100 = 2.5 µM) and VEGF signaling-dependent intersomitic vessel formation (EC50 = 5 µM) in zebrafish embryo in vivo. Commonly used in combination with AMPK activators AICAR (Cat. No. 123040) and/or Metformin (Cat. No. 317240) for studying AMPK-dependent cellular events in vitro and physiological responses in animals in vivo. Packaging 1 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes EC100 = 2.5 µM against BMP pathway-dependent dorsoventral development; EC50 = 5 µM against VEGF signaling-dependent intersomitic vessel formation in zebrafish embryo in vivo Primary Target AMPK Product competes with ATP. Reversible: yes Target IC50: 25.1, 148, and 234.6 nM, against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity, respectively Packaging Packaged under inert gas Warning Toxicity: Irritant (B) Physical form Supplied as a 10 mM (1 mg/250 µl) solution of AMPK Inhibitor, Compound C (Cat. No. 171260) in DMSO. Reconstitution Following initial use, aliquot and freeze (-20°C). Once opened, stock solutions are stable for up to 3 months at -20°C. Other Notes Hao, J., et al. 2010. ACS Chem.Biol.5, 245. Kim, E.K., et al. 2004. J. Biol. Chem.279, 19970. Lee, M., et al. 2003. J. Biol. Chem.278, 39653. Inoki, K., et al. 2003. Cell115, 577. Fryer, L.G., 2002. FEBS Lett.531, 189. Zhou, G., et al. 2001. J. Clin. Invest.108, 1167.